Background Opioid receptors are implicated in cancer progression and long-term patient
outcomes. However, the prognostic significance, underlying mechanisms, and therapeutic …

Opioids are the most popular drugs for both acute and chronic pain management. The G
protein-coupled mu-opioid receptor (MOR) is the therapeutic target for most clinically used …

Hepatocellular carcinoma (HCC) is the most prevalent subtype of liver cancer. Anesthetic
regimens possibly influence cancer development. Exploration of novel, effective targets for …

The mu-opioid receptor (MOR), a membrane-bound G protein-coupled receptor, is the main
target for opioids in the nervous system. MOR1 has been found in several types of cancer …

Mu opioids are among the most widely used drugs for patients with cancer with both acute
and chronic pain as well as in the perioperative period. Several retrospective studies have …

Preclinical evidence has shown increased expression of mu opioid receptor 1 (MOR-1) in
colorectal cancer although its association with disease-free and overall survival (DFS and …

BACKGROUND: The possibility that μ opioid agonists can influence cancer recurrence is a
subject of recent interest. Epidemiologic studies suggested that there were differences in …

Background We and others have previously demonstrated that the μ-opioid receptor (MOR)
is overexpressed in several human malignancies. There is a seven-fold increase in MOR in …

Opiates have long been used as analgesics to relieve pain associated with various medical
conditions. μ-opioid receptor (MOR) is the main member of the opioid receptor super-family …

Background Opioid receptors have become increasingly implicated in cancer progression
and long-term patient outcomes. However, the expression and significance of the κ-opioid …